Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Overview of attention for article published in Journal of Clinical Oncology, September 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

policy: 1 policy source
patent: 2 patents

f1000: 1 research highlight platform

Citations

dimensions_citation: 236 Dimensions

Readers on

mendeley: 139 Mendeley

Summary Policy documents Patents Research highlights Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

Masked activatable interferon constructs

Grant US-11667687-B2

United States of America

Activatable cytokine constructs and related compositions and methods

Grant US-11365233-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.